RedHill Biopharma (RDHL) Profit After Tax (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Profit After Tax data on file, last reported at $101.2 million in Q2 2023.

• Profit After Tax for Q2 2023 came in at $101.2 million, up 964.51% year-over-year; the trailing twelve-month figure through Jun 2023 was $11.6 million (up 115.51% YoY), and the FY2025 annual result was -$8.1 million, down 2344.44% from the prior year.
• Profit After Tax rose to $101.2 million in Q2 2023 per RDHL's latest filing, from -$50.2 million in the prior quarter.
• Over five years, Profit After Tax peaked at $101.2 million in Q2 2023 and troughed at -$50.2 million in Q1 2023.
• A 5-year average of -$2.6 million and a median of -$11.3 million in 2019 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2020 and 2023: Profit After Tax plunged 308.12% in 2020, then soared 964.51% in 2023.
• A 5-year view of Profit After Tax shows it stood at $11.7 million in 2019, then slumped by 308.12% to -$24.3 million in 2020, then slipped by 0.17% to -$24.4 million in 2021, then surged by 84.7% to -$3.7 million in 2022, then jumped by 2815.02% to $101.2 million in 2023.
• Business Quant data shows RDHL's Profit After Tax at $101.2 million in Q2 2023, -$50.2 million in Q1 2023, and -$3.7 million in Q4 2022.